ARECOR THERAPEUTICS PLC - FY25 Results

Arecor Therapeutics PLC’s latest investor update highlights solid company performance, strategic progress, and a focused growth strategy in high-value cardiometabolic markets. The clinical-stage biotech reported strengthened financial results, including improved revenue, reduced operating costs, and a bolstered balance sheet following a $11 million non-dilutive royalty financing, extending cash runway to Q2 2027. The company’s lead asset, AT278—an ultra-concentrated, ultra-rapid acting insulin—continues to advance toward Phase 2 clinical trials in partnership with Sequel MedTech, with positive FDA feedback supporting its regulatory pathway and commercial potential. Targeting a multi-billion-dollar market opportunity, AT278 is positioned to enhance automated insulin delivery systems, improving patient outcomes while addressing unmet needs in diabetes care. Alongside this, Arecor is progressing its proprietary oral peptide delivery platform, with early-stage data demonstrating promising stability and ongoing pharmacokinetic studies aimed at improving bioavailability. The company’s dual-platform approach, supported by strategic partnerships with major pharma players, underpins long-term revenue growth potential and pipeline expansion. With a disciplined capital allocation strategy, strong R&D focus, and clear clinical milestones ahead, Arecor remains well positioned to deliver value through innovation, partnerships, and scalable commercial opportunities in global healthcare markets.